Neuromyelitis optica in a paediatric patient: a case report
DOI:
https://doi.org/10.18203/2349-3291.ijcp20242745Keywords:
Neuromyelitis optica, Follow up, Relapse, Methylprednisolone, Prednisolone, Azathioprine, RituximabAbstract
Neuromyelitis optica is a multifocal demyelinating disease of the central nervous system that predominantly affects the spinal cord and optic nerves, with variable clinical features including motor weakness in limbs, bowel and bladder affection and loss of vision. The disease is characterized by poor or no recovery. Magnetic resonance imaging (MRI) of spine with contrast shows hyperintense lesions involving contiguous segments with a normal MRI brain. CSF studies shows anti aquaporin 4 antibodies. Visual evoked potential of eyes shows marked reduction of optic nerve function. We report a case of eight year old girl who presented with diminished vision in eyes (right >left) and weakness in all four limbs. Clinical features and investigations were suggestive of NMO. She was treated with inj. methylprednisolone for 5 days followed by oral prednisolone in tapering dose for 6 weeks. The child improved of hemiparetic gait and power in the left side. Vision in the left eye did not deteriorate further. Repeat MRI showed the resolution of previous spinal lesions. Follow up of the child over seven years has multiple admissions due to relapses. In the third admission child was given again 5 days of inj. methylprednisolone followed by azathioprine for two months. On the seventh admission due to relapse, inj. rituximab 500 mg and inj. methylprednisolone 500 mg was given and repeated every 6 months. In the last follow up in June 2024, the child is clinically stable with improvement in gait and no further deterioration of vision and no bowel or bladder affection.
References
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome) Neurology. 1999;53(5):1107-14.
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-12.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89.
Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: State-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10(9):493-506.
Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al. Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659-66.
Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA. Neuromyelitis optica treatment: Analysis of 36 patients. Arch Neurol. 2010;67(9):1131-6.
Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128-33.
Chen H, Zhang Y, Shi Z, Feng H, Yao S, Xie J, et al. The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin Neuropharmacol. 2016;39(2):81-7.
Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1342-8.
Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81(14):1197-204.
Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-2.
Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-8.
Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310-5.
Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 2011;17(10):1225-30.
Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70(9):1110-7.
Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, et al. Rituximab as first-line therapy in neuromyelitis optica: Efficiency and tolerability. J Neurol. 2015;262(10):2329-35.
Van Vollenhoven RF, Emery P, Bingham CO, 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502.
Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, et al. Worldwide Incidence and Prevalence of Neuromyelitis Optica. Neurololgy. 2021;96(2):59-77.
